Literature DB >> 26572758

Serum carcinoembryonic antigen-related cell adhesion molecule 1 level in postmenopausal women: correlation with β-catenin and bone mineral density.

C Ma1, B Shuai1, L Shen2, Y P Yang1, X J Xu1, C G Li1.   

Abstract

UNLABELLED: Many epidemiological studies have shown that in some tumors carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and β-catenin appear to be related. However, it remains to be established whether CEACAM1 is related to β-catenin in osteoporosis. Here, we reveal that CEACAM1 might influence the canonical Wnt/β-catenin pathway to modulate bone metabolism in postmenopausal osteoporosis.
INTRODUCTION: The aim of this study is to assess the serum level of CEACAM1 in postmenopausal women and its correlation with β-catenin and bone mineral density (BMD).
METHODS: The BMD was measured at the lumbar spine (L1-L4) or the femoral neck using dual-energy X-ray absorptiometry (DXA). Serum CEACAM1, β-catenin, receptor activator of nuclear factor kappa-B (RANKL), osteoprotegerin (OPG), β-isomerized C-terminal crosslinking of type I collagen (β-CTX), intact N-terminal propeptide of type I collagen (PINP), estradiol, and insulin were measured in 350 postmenopausal women. Patients were divided according to lumbar spine or femur neck T-scores into osteoporosis (group I), osteopenia (group II), and normal bone mineral density, the latter serving as control.
RESULTS: Serum CEACAM1 levels were significantly lower in group I and II compared to those in control subjects (P < 0.001). Serum CEACAM1 levels correlated positively with β-catenin and BMD, but correlated negatively to the ratio between RANKL and OPG.
CONCLUSION: This study provides evidence that decreased serum CEACAM1 levels are related to low BMD in postmenopausal women, and that serum CEACAM1 levels correlated positively to β-catenin. It suggests that CEACAM1 might influence the canonical Wnt/β-catenin pathway to modulate bone metabolism.

Entities:  

Keywords:  Bone mineral density; Carcinoembryonic antigen-related adhesion molecule 1; Postmenopausal osteoporosis; β-catenin

Mesh:

Substances:

Year:  2015        PMID: 26572758     DOI: 10.1007/s00198-015-3408-3

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  39 in total

1.  Bone versus immune system.

Authors:  J R Arron; Y Choi
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

2.  RANKL and OPG activity is regulated by injury size in networks of osteocyte-like cells.

Authors:  Lauren E Mulcahy; David Taylor; T Clive Lee; Garry P Duffy
Journal:  Bone       Date:  2010-09-18       Impact factor: 4.398

3.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

4.  Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.

Authors:  Chenghai Li; Zhengfeng Yang; Zhenxi Li; Yu Ma; Lipeng Zhang; Chunbing Zheng; Wenwei Qiu; Xian Wu; Xiu Wang; Hui Li; Jie Tang; Min Qian; Dali Li; Ping Wang; Jian Luo; Mingyao Liu
Journal:  J Bone Miner Res       Date:  2011-03       Impact factor: 6.741

5.  The tumor growth-inhibiting cell adhesion molecule CEACAM1 (C-CAM) is differently expressed in proliferating and quiescent epithelial cells and regulates cell proliferation.

Authors:  B B Singer; I Scheffrahn; B Obrink
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

Review 6.  Regulation of bone mass by Wnt signaling.

Authors:  Venkatesh Krishnan; Henry U Bryant; Ormond A Macdougald
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

Review 7.  Bones for the future.

Authors:  I T Boyle
Journal:  Acta Paediatr Scand Suppl       Date:  1991

8.  Direct interaction of tumor suppressor CEACAM1 with beta catenin: identification of key residues in the long cytoplasmic domain.

Authors:  Lan Jin; Yun Li; Charng-Jui Chen; Mark A Sherman; Keith Le; John E Shively
Journal:  Exp Biol Med (Maywood)       Date:  2008-04-29

9.  Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1.

Authors:  S Huang; M Kaw; M T Harris; N Ebraheim; M F McInerney; S M Najjar; B Lecka-Czernik
Journal:  Bone       Date:  2010-01-04       Impact factor: 4.398

10.  Serum β -Catenin Levels Associated with the Ratio of RANKL/OPG in Patients with Postmenopausal Osteoporosis.

Authors:  Xiao-Juan Xu; Lin Shen; Yan-Ping Yang; Rui Zhu; Bo Shuai; Cheng-Gang Li; Man-Xiang Wu
Journal:  Int J Endocrinol       Date:  2013-04-22       Impact factor: 3.257

View more
  2 in total

1.  Integrating transcriptome-wide association study and mRNA expression profiling identifies novel genes associated with bone mineral density.

Authors:  M Ma; D-G Huang; X Liang; L Zhang; S Cheng; B Cheng; X Qi; P Li; Y Du; L Liu; Y Zhao; M Ding; Y Wen; X Guo; F Zhang
Journal:  Osteoporos Int       Date:  2019-04-15       Impact factor: 4.507

2.  Systemic tracking of diagnostic function modules for post-menopausal osteoporosis in a differential co-expression network view.

Authors:  Chuan-En Wang; Jin-Qiang Wang; Yuan-Jian Luo
Journal:  Exp Ther Med       Date:  2018-01-23       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.